

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

A critical analysis of New Zealand's *Psychoactive Substances Act*
2013 and its implementation process

A thesis presented in partial fulfilment of the requirements for the degree of

Doctor of Philosophy

In

Public Health

at Massey University, Albany, New Zealand.

Marta Rychert

2017

Abstract

Introduction: In July 2013, the New Zealand Parliament passed the *Psychoactive Substances Act* (PSA), the world's first law to regulate the availability of new psychoactive substances (NPS, "legal highs", LH). Under the "interim PSA regime" 47 products were permitted to be sold subject to new retail and other regulations. In May 2014, the Government abruptly ended the interim regime following public protests. This thesis aims to critically evaluate the PSA and its implementation.

Methods: A mixed methods approach combined qualitative and quantitative methods of data collection and analysis. Legal analysis of the PSA and related legislation, and content analysis of parliamentary debates and public submissions were completed. Semi-structured interviews were then conducted with key informants (KI) including politicians, government officials, health professionals, and LH industry actors (n=30). Questions about health perceptions and social acceptability of approved products were added to an annual survey of police arrestees (n=834). Analyses of primary data included thematic analysis of interview transcripts and statistical analysis of data from the arrestee survey.

Results: The legal definition of "psychoactive substance" (s. 8, 9(1) PSA) overlaps with other regulatory regimes (e.g. medicines, dietary supplements) resulting in an unclear legal status for some products. Interviewed KIs identified a number of issues with the "interim regime", including the safety of interim products, speed and efficiency of withdrawing problem products, the lack of regulations on price and retail opening hours, slowness of developing regulations for the full PSA regime, and the effectiveness of communicating the new policy to stakeholders and the public. As the market commercialised, the LH industry adopted business and lobbying strategies previously attributed to the alcohol and tobacco sectors, including targeting vulnerable customers. Surveyed police arrestees considered approved synthetic cannabis (SC) products higher health risk and less socially acceptable than alcohol, tobacco and many illegal drugs, reflecting problems with interim product approvals. The ban on animal testing of prospective products is likely to prevent further implementation of the PSA, unless a new political consensus is achieved.

Conclusions: The issues experienced during PSA implementation highlight the significant challenges of establishing a legal market for psychoactive products. The time, resources and planning required to successfully implement the PSA may have been underestimated.

Preface

Personal statement

I studied law in Warsaw (Poland) and Lisbon (Portugal), and graduated with a Master's Degree in Law from the University of Warsaw in April 2013. I also worked as a journalist for a couple of years, including as an individual contractor with the Ministry of Justice in Poland. I completed formal education in media studies, obtaining a bachelor's degree from the National School of Film, Television and Theatre in Łódź (Poland) in September 2011. This varied educational and professional background gives me a unique approach to studying laws, with a particular interest in "law in action", where the focus is on how law works in the real world and how it is applied in society rather than purely how it stands in statutes.

I developed my interest in laws controlling access to illegal drugs during a three-month study visit at the Centre for Legal and Economic Research, University of Porto (Portugal) in 2012. Since then my interest in the field has evolved.

I am originally from Poland, a country in Central Europe particularly hard hit by the problem of new psychoactive substances (NPS), with mass poisoning reported in 2010 and 2015. A "blanket ban" on supply of NPS products implemented in Poland in 2010 has not proved to be a long-term solution to the NPS problem. This raised my interest in alternative legal approaches to the NPS problem. During the 10 months of my internship with the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 2013, my interest in the issue of controlling NPS developed further.

It was June 2013, at the 3rd International Multidisciplinary Forum on New Drugs (Lisbon, Portugal), that I first learnt about New Zealand's regulated market approach to new psychoactive substances from a presentation by Associate Professor Chris Wilkins. In March 2014 I applied for a PhD scholarship to study how the New Zealand's market for NPS established under the Psychoactive Substances Act (PSA) 2013 worked in practice.

By the time my PhD study began in June 2014 the interim regulated market established under the PSA had been ended. This unforeseen change in the regulatory environment necessitated substantial changes in the initial PhD research proposal. However, it also raised a new set of questions about what issues and challenges with the PSA had resulted in the abrupt ending of the interim regime. My PhD aimed to investigate and analyse these issues and challenges with the intention of enhancing any future implementation of the PSA and identifying learnings for proposed regulatory regimes for other psychoactive substances.

Acknowledgements

Associate Professor Chris Wilkins and Professor Karen Witten supervised this Thesis and I would like to acknowledge their advice and guidance. In particular, I would like to thank my primary supervisor Associate Professor Chris Wilkins for his comments on drafts of research articles included in this thesis and continuous support in my research, publishing and learning process. I would like to acknowledge the supportive research environment provided by the SHORE and Whāriki Research Centre and the administrative and editing help from SHORE staff Jan Sheeran and Lisa Morice.

This study would not be possible without participants who agreed to share their experiences about implementation of the Psychoactive Substances Act 2013. I am grateful to all study participants, who I cannot acknowledge here by name due to confidentiality reasons. Also, I would like to thank staff from the Ministry of Health for their help with the legislation and feedback provided. Anonymous reviewers of journal articles published during this PhD also provided valuable comments on the manuscripts.

I would like to thank my family for their support and encouragement.

About dissertation “by publications”

This thesis has been prepared by joining together six journal articles published or submitted for publication during the course of the PhD candidature. It is a “PhD by publication”, where each results chapter constitutes a research article with a structure typical for peer-reviewed journals. It has been written in line with Massey University Guidelines on PhD Thesis by Publication (Massey University, no date).

The thesis works as an integrated whole, with Chapters 1, 2 and 3 outlining the research context and methodology and Chapter 10 synthesising and discussing findings from all published papers. The results chapters (Chapters 4–9) constitute published research papers.

The table below contains information about publications comprising the results chapters of this thesis, and other research outputs published during this PhD. As the author of this PhD thesis, I hold primary authorship of all research papers, with my thesis supervisors and SHORE & Whāriki Research Centre support staff who contributed significantly to the research listed as co-authors. Appendix A contains a detailed statement of contribution to each research paper and other outputs published during this PhD. I have received permission from all copyright holders to reprint journal articles and other outputs in this thesis.

PhD content	Article title and journal, or full reference (if published)	Publication status
Chapter 4	Rychert, M., & Wilkins, C. (2016). What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties. <i>Drug Testing and Analysis</i> , 8(8), 768-778. Doi: 10.1002/dta.1943	published
Chapter 5	Rychert, M., Wilkins, C. & Witten, K. (2017). Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances (NPS) ('legal highs') in New Zealand. <i>Drug and Alcohol Review</i> . Published online 23 Feb 2017. Doi: 10.1111/dar.12507	published
Chapter 6	Rychert, M., Wilkins, C. & Witten, K. (2017). “Lost in translation”: issues with the establishment of a legal market for 'low risk' psychoactive products ('legal highs') in New Zealand. <i>Drugs: Education, Prevention & Policy</i> . Published online 2 Feb 2017. Doi: 10.1080/09687637.2017.1282422	published
Chapter 7	Rychert, M. & Wilkins, C. (2016). Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand. <i>International Journal of Drug Policy</i> , 37, 90-97. Doi: http://dx.doi.org/10.1016/j.drugpo.2016.08.011	published

Chapter 8	Rychert, M., Wilkins, C., Parker, K. & Witten, K. Are government-approved “legal highs” perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand. <i>Drug and Alcohol Review</i> . Forthcoming.	accepted
Chapter 9	Rychert, M. & Wilkins, C. (2015). The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) (‘legal highs’) in New Zealand: Issues and options for resolution. <i>International Journal of Drug Policy</i> , 26(12), 1273-1278. Doi: http://dx.doi.org/10.1016/j.drugpo.2015.08.006	published
Appendix G	Rychert, M. & Wilkins, C. (2015) Did we have the wrong debate about Elixinol™ and medicinal cannabis? [Letter]. <i>New Zealand Medical Journal</i> , 128(1521), 69-70.	published
Appendix H	Rychert, M. & Wilkins, C. (2016). Thirty-one psychoactive plants exempted from New Zealand's Psychoactive Substances Act 2013 [Letter]. <i>Addiction</i> , 112(1), 181-182. Doi: 10.1111/add.13526	published
Appendix I (some sections incorporated in Chapter 2, s 2.1, 2.3)	Rychert, M., & Wilkins, C. (2017), <i>New Zealand's pre-market approval regime for 'low risk' new psychoactive substances (NPS, 'legal highs') - a regulatory alternative to prohibition</i> , in: A. Malczewski (Ed.) <i>Monitoring drugs and drug addiction on local level</i> . Warsaw, Poland: Information Centre for Drugs and Drug Addiction. (Published in English and Polish)	published
Appendix K	Rychert, M., & Wilkins, C. (2015). Is the recent ban on animal testing of legal high products a fatal blow to the development of a legal market for ‘low-risk’ psychoactive products in New Zealand? [Letter] <i>Addiction</i> , 110(4), 713-714. Doi: 10.1111/add.12853	published
Appendix L	Wilkins, C., and Rychert, M. (2017) Recent developments with the New Zealand regulated market approach to ‘low-risk’ psychoactive products. <i>Addiction</i> , 112: 34–36. doi: 10.1111/add.13495 .	published
Appendix M	Wilkins, C., Rychert, M., Byrska, B., Van Hout, M., Corazza, O., & A.Roman-Urrestarazu (2017). “Exploring novel policy responses to NPS and ‘legal highs’ in New Zealand, Poland, Republic of Ireland & the United Kingdom”. <i>Novel Psychoactive Substances. Policy, Economics and Drug Regulation</i> . Ed. Ornella Corazza & Andres Roman-Urrestarazu. Springer Nature, 2017	published

Table of Contents

Abstract	iii
Preface.....	iv
Personal statement	iv
Acknowledgements	v
About dissertation “by publications”	vi
List of figures	xiv
List of tables.....	xiv
List of acronyms.....	xv
Chapter 1: Research context	1
1.1 The challenge of new psychoactive substances (NPS)	1
1.1.1 The evolution of NPS phenomenon and definitions	2
1.1.2 NPS market characteristics	4
1.1.3 Health risks associated with NPS use	7
1.2 New policy responses to NPS	10
1.2.1 Rapid and emergency procedures.....	12
1.2.2 Generic, analogue and neurochemical definitions.....	12
1.2.3 Application of existing administrative laws.....	13
1.2.4 “Blanket bans” on NPS supply	14
1.2.5 Summary of issues with prohibiting NPS on national level	15
Chapter 2: New Zealand’s regulated market response to NPS	17
2.1 The early emergence of legal highs in New Zealand	17
2.2 Issues raised during consultation stage for the PSA.....	19
2.2.1. Issues raised in public submissions to the Psychoactive Substances Bill	19
2.2.1.1 Reasons behind support and opposition to regulation of the market	19
2.2.1.2 Recommendations made in public submissions	20
2.2.2 Issues raised in parliamentary debates	21
2.3 Regulatory mechanisms under the PSA	23

2.4 The interim regulated market under the PSA.....	24
2.4.1 Managing products approved on the interim market	24
2.4.2 Interim licensed retailers and community protests.....	26
2.4.3 The Psychoactive Substances Amendment Act and ending of the interim regime	27
2.5 Existing evidence and evaluations of the PSA.....	28
2.6 Knowledge gaps and PhD research focus	29
2.7 Research aims and objectives	31
2.8 Structure of the thesis	32
Chapter 3: Theoretical framework and methodology	35
3.1 Theoretical framework	35
3.2 A note on epistemological position	35
3.3 Mixed methods approach	36
3.3.1 Document analysis	39
3.3.1.1. Content analysis of written submissions to the PSA.....	39
3.3.1.2 Thematic analysis of parliamentary debates	40
3.3.1.3 Legal analysis of the PSA and other legal sources	40
3.3.2 Interviews with key informants	41
3.3.3 Thematic analysis of interview transcripts	42
3.3.4 Statistical analysis of data from NZ-ADUM.....	42
3.3.5 Review of academic literature	43
Chapter 4: What products are considered psychoactive under New Zealand’s regulated legal market for new psychoactive substances (NPS, ‘legal highs’)? Implications for law enforcement and penalties	45
Abstract.....	46
Introduction	47
Ambiguities in legal classifications of products with psychoactive properties	49
Kava (Piper methysticum)	49
Salvia divinorum.....	51
Nitrous oxide (N2O)	53
DMBA (“Frenzy”).....	54
25I-NBOMe	54
The role of marketing and labelling in the classification of psychoactive products.....	55
Implications for policing and prosecuting in criminal cases	57

Psychoactive substances vs controlled drug analogues.....	59
Conclusions and discussion	60
Chapter 5: Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances (NPS) ('legal highs') in New Zealand	65
Abstract	66
Introduction.....	67
Background: Identifying products to receive interim approvals and developing the safety monitoring system	68
Methods	69
Results	70
PSA criteria used to select products for interim approval	70
Applying the PSA criteria for products in practice	70
Perceived safety of interim approved products	71
Quality control of interim products and its unintended consequences	72
Availability of data to monitor the safety of interim approved products	73
Quality of data on adverse events.....	74
Consistency of product withdrawal decisions.....	75
Speed of withdrawing harmful products from the market	76
Discussion and Conclusions	76
Chapter 6: "Lost in translation": issues with the establishment of a legal market for 'low risk' psychoactive products ('legal highs') in New Zealand	79
Abstract	80
Introduction.....	81
Background: interim retail framework and the role of local communities in the PSA ..	82
Methods	83
Results	84
Licensing retailers for the interim PSA market.....	84
Problems with interim licensed outlets.....	85
The 'bottleneck effect'	86
Backlash from local communities.....	86
Slowness in implementation of LAPPs	87
Opposition from local councils.....	88
Engagement with the media and public opinion	88

Regulatory management and workload during the interim regime	89
Conclusions and Discussion	90
Chapter 7: Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.....	
95	95
Abstract.....	96
Introduction	97
Historical background: the evolution of LHI in New Zealand	97
Methods.....	100
Results.....	102
LHI motivations	102
Keeping a distance from "Big Tobacco" and "Big Alcohol"	102
Political advocacy of LHI.....	103
The challenge of industry growth	103
Benefits and pitfalls of industry professionalization	104
Marketing towards youth and low-income customers.....	104
The decline in product prices.....	105
Price control as a means to ensure a more responsible client base.....	105
Brand reputation for product safety.....	106
LHI self-regulation and its effectiveness	106
The impact of the global legal high market	107
Discussion and conclusions.....	108
Chapter 8: Are government-approved products containing new psychoactive substances (NPS) perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand. 113	
113	113
Abstract.....	114
Introduction	115
Methods.....	117
Measures.....	118
Analysis	118
Results.....	119
Demographics	119
Perceived health risk and social acceptability of approved legal SC and approved legal PP compared to other drugs	120
Associations between drug use, sociodemographic characteristics and health and social acceptability score	121

Summary and discussion	123
Limitations	125
Conclusions.....	125
Chapter 9: The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution	127
Abstract	128
Introduction.....	129
Political background: evolution of the animal testing provisions under the new regime.....	130
Methods	131
Results	132
Scenario 1: Animal testing ban is revoked or modified.....	132
Scenario 2: Wait for scientific progress on non-animal tests.....	133
Scenario 3: Applicants use non-validated in vitro test methods.....	134
Scenario 4: Unsuccessful applicants challenge rejected applications in court	134
Scenario 5: 'Creative compliance' – human trial data is presented without animal test data.....	135
Scenario 6: Philosophical reconceptualisation of the benefits from recreational psychoactive products.....	136
Discussion and Conclusions.....	137
Chapter 10: Discussion and conclusions	139
10.1 Synthesis of findings.....	139
10.1.1. Identified challenges with implementing the PSA during the “interim regime”	139
10.1.2. Critique of the PSA policy process.....	141
10.1.3. Critique of the PSA legislation	143
10.1.4 Social perceptions of the regulated market approach to NPS	145
10.2 Research implications.....	147
10.2.1 Comparison of the PSA and cannabis law reforms in Colorado, Washington and Uruguay	147
10.2.2 Lessons for other jurisdictions wanting to establish legal markets for recreational drugs (including cannabis)	153
10.2.3 Recommendations for the future implementation of the PSA in New Zealand	155
10.3 Research strengths and limitations	161

10.4 Areas for future research.....	162
Bibliography	164
Appendices.....	188
Appendix A: Statement of contribution to Doctoral Thesis containing publications .	188
Appendix B: Categorisation of NPS compounds referred to in this thesis	192
Appendix C: Interview protocol	193
Appendix D: Participant information sheet	197
Appendix E: Participant consent form	198
Appendix F: Transcript release authority form.....	199
Appendix G: Letter published in the <i>NZMJ</i> : Did we have the wrong debate about Elixinol™ and medicinal cannabis?	200
Appendix H: Letter published in <i>Addiction</i> : Thirty-one psychoactive plants exempted from New Zealand's Psychoactive Substances Act 2013	202
Appendix I: Publication for the Polish Drug Information Centre: New Zealand's pre-market approval regime for 'low risk' new psychoactive substances (NPS, 'legal highs') - a regulatory alternative to prohibition	204
Appendix J: Univariate analysis results (preliminary analysis for Chapter 8)	212
Appendix K: Letter published in <i>Addiction</i> : Is the recent ban on animal testing of legal high products a fatal blow to the development of a legal market for 'low-risk' psychoactive products in New Zealand?	219
Appendix L: Letter published in <i>Addiction</i> : Recent developments with the New Zealand regulated market approach to 'low-risk' psychoactive products.	223
Appendix M: Co-authored book chapter: "Exploring novel policy responses to NPS and 'legal highs' in New Zealand, Poland, Republic of Ireland & the United Kingdom" ...	226

List of figures

Figure 1: Number of NPS reported to the EU and UN.....	5
Figure 2: NPS groups categorised by pharmacological effect (data up to 2015), source: UNODC EWA (2017a).....	6
Figure 3: Framework for the review of national responses to NPS	11
Figure 4: Framework for the review of national responses to NPS, with examples.	11
Figure 5: SC-related calls received by the National Poisons Centre (October 2010 – February 2016).....	25
Figure 6: Logic model of the Public Health Law Research (Burriss et al., 2010)	35
Figure 7: Research process flowchart.....	44
Figure 8: Schematic representation of relationships between definitions of psychoactive substance and other products with potential psychoactive properties	49
Figure 9: Mean health risk and social acceptability scores for all drugs	121
Figure 10: Progress in the implementation of the PSA	131
Figure 11: Implementation timeline of “regulated drug market” law reforms in NZ, Colorado, Washington and Uruguay.....	148

List of tables

Table 1: Support and opposition for the PSB by submitter type.....	20
Table 2: Themes identified in the analysis of parliamentary readings on the PSB	22
Table 3: Interim approved products withdrawn during the interim regime and products which remained on the interim market until PSAA (by active ingredient and declared concentration). Compiled from data archived on PSRA website.....	26
Table 4: Objectives of the PhD and rationales for research papers.....	31
Table 5: Typology of Public Health Law Studies (Burriss et al., 2010) and their relevance to this thesis.....	38
Table 6: Categories of products or substances exempted from the PSA regime.....	50
Table 7: Psychoactive substances which can potentially sit in multiple regulatory regimes.....	52
Table 8: Maximum penalties for offences under DSR, FA, MA, PSA and MODA	57
Table 9: Demographic characteristics of police arrestee sample.....	120
Table 10: Association between drug use and demographic variables and health risk and social acceptability scores	122
Table 11: Association between frequent SC users and other drug user groups and social acceptability scores	123
Table 12. Evaluation of scenarios to overcome the animal test ban impasse	137
Table 13: Comparison of selected issues in design and implementation of regulatory responses to recreational drugs in NZ, Colorado, Washington and Uruguay	149

List of acronyms

ECJ	European Court of Justice
EMCDDA	European Monitoring Centre for Drugs and Drug Addiction
EU	European Union
EWA	Early Warning Advisory (UNODC)
EWS	Early Warning System (EU)
IDMS	Illicit Drug Monitoring System (IDMS – NZ)
KI	Key informant
LAPP	Local Approved Product Policy (NZ)
LH	‘Legal highs’
LHI	‘Legal high’ industry
MODA	Misuse of Drugs Act (1971 – UK; 1975 – NZ)
MOH	Ministry of Health
NGO	Non-governmental organisation
NPS	New psychoactive substances
NZ	New Zealand
NZ-ADUM	New Zealand Arrestee Drug Use Monitoring study
NZLC	New Zealand Law Commission
P	Participant
PSA	Psychoactive Substances Act (2013 – NZ, 2016 – UK)
PSAA	Psychoactive Substances Amendment Act (2014 - NZ)
PSB	Psychoactive Substances Bill (i.e. “draft” law, before vote in Parliament - NZ)
PSEAC	Psychoactive Substances Expert Advisory Committee (NZ)
PSRA	Psychoactive Substances Regulatory Authority (NZ)
RSR	Restricted Substances Regime (NZ)
SC	Synthetic cannabinoids
TCDN	Temporary Class Drug Notice (NZ)
TCDO	Temporary Class Drug Order (UK)

UN	United Nations
UNODC	United Nations Office on Drugs and Crime
UK	United Kingdom
WHO	World Health Organization